| December 19, 2013 | ISSUE NUMBER 331 VOL 12 |
Social Media
2014: The Year of Digital Pharma?
2014 might be the year that pharma finally has to get really serious about digital, at least if the analysts are right. Peter Houston reports ...Read more
Leadership Strategy
Fred Hassan: Musings on the Biopharma Learning Curve
The one area where many CEOs trip up is failing to understand the essential role of communication skills in bonding and building trust among warring executives, skittish workers and skeptical outside stakeholders, says Fred Hassan, now managing director of Warburg Pincus ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
Employment Survey
Pharma Industry Optimism Outweighs Concerns for Job Security
Amid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed muted optimism despite stagnant employment options in Pharmaceutical Technology’s latest employment survey ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
Therapeutic Areas: COPD and Asthma
Deep Breadth: GSK Doubles Down on COPD and Asthma
Approved in May (in the US) and November (in the EU), GSK’s fluticasone furoate/vilanterol dry powder combo inhaler for Chronic Obstructive Pulmonary Disease (COPD) and asthma is the first of four late-stage respiratory products aimed at a capturing a piece of the expanding COPD and asthma market ...Read more
|
|
|
|
 //Halozyme Therapeutics, Inc. (San Diego, CA) announced that Helen Torley will be joining Halozyme as President and Chief Executive Officer on January 6, 2014.//Chimerix, Inc. (Durham, NC) announced the appointment of Linda M. Richardson as Chief Commercial Officer.//Theo Melas-Kyriazi, CFO of Levitronix Technologies LLC and a Director of Valeant Pharmaceuticals International, joined the Board of Directors at Moderna Therapeutics, Inc. (Cambridge, MA).//Azure Biotech Inc. (New York, NY) appointed Ralph Makar as Chief Executive Officer.// |
|
|
|
|
|
 |
|
|
|
| |
|
|
|
 |
|
 |
In which area do you think your company should now be investing to increase profitability?
|
|
|
|
